Skip to main content
Listen in: the latest news on Biosimilars! Listen to our new Coffee with ClearScript for the latest news on Biosimilars!

The clear choice in pharmacy benefit management.

Insights Archive

Nasal spray bottle resembling Epinephrine with multiple nasal spray medication bottles in background.

November 4, 2024

Neffy® (brand name: epinephrine nasal spray)

Neffy® (epinephrine nasal spray) was approved on August 9, 2024, for the emergency treatment of allergic reactions (type I), including those that are life-threatening (anaphylaxis), in adult and pediatric patients weighing at least 66 pounds.

pen injectable representing biosimilar medication.

November 3, 2024

Humira® biosimilars in focus

For years, Humira® (adalimumab) has been a significant driver of healthcare costs due to its high price and utilization. With the introduction of several Humira biosimilars, learn how ClearScript has been monitoring the landscape and adapting strategies to provide members access to cost-effective therapy options for better health.

Cover image that reads: Coffee with CLEARSCRIPT - Fiduciary Stewardship: Patients not Profits - What does that mean and how is ClearScript different?

September 19, 2024

Fiduciary Stewardship: Patients not Profits

Why are the Big Three the most significant cost drivers in pharmacy benefits today? Because they put profits before patients. Fortunately, ClearScript is different. Listen to this coffee chat to learn how you can ensure your PBM is putting your members before profits.

A photo of a tape measure and pen injectors

July 15, 2024

Drug Spotlight: liraglutide (brand name Victoza)

On June 24, 2024, drug manufacturer Teva Pharmaceuticals announced the launch of an authorized generic formulation of Novo Nordisk’s Victoza (liraglutide). This marks the first generic glucagon-like peptide-1 (GLP-1) agonist available in the U.S. market.